Margit Mitterbauer
Vienna, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Clinical Trials in Graft-Versus-Host Disease: Changes in Study Characteristics, Investigated Drugs, and Endpoints Over Time.
Journal: Transplantation and cellular therapy
Published: April 29, 2026
Post-transplant ring sideroblasts are common in haploidentical peripheral blood stem cell transplantation but not linked to SF3B1 mutations.
Journal: Clinical chemistry and laboratory medicine
Published: January 16, 2026
Retrospective Analysis: S100 as Marker for Immune Effector Cell-Associated Neurotoxicity Syndrome.
Journal: Oncology
Published: November 28, 2024
S100 as marker for immune effector cell-associated neurotoxicity syndrome.
Journal: Wiener klinische Wochenschrift
Published: August 13, 2024
Diverse macrophage populations contribute to distinct manifestations of human cutaneous graft-versus-host disease.
Journal: The British journal of dermatology
Published: July 07, 2023
Emergency Department Utilization Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Retrospective Longitudinal Analysis of 557 Patients.
Journal: Transplantation and cellular therapy
Published: December 12, 2022
Epigenetic regulation of T cell lineages in skin and blood following hematopoietic stem cell transplantation.
Journal: Clinical immunology (Orlando, Fla.)
Published: August 31, 2022
Cytokine Release Syndrome during Antithymocyte Globulin/Anti-T Lymphocyte Globulin Serotherapy for Graft-versus-Host Disease Prophylaxis before Allogeneic Hematopoietic Stem Cell Transplantation: Incidence and Early Clinical Impact According to American Society of Transplantation and Cellular Therapy Grading Criteria.
Journal: Transplantation and cellular therapy
Published: December 20, 2021
Long-term skin-resident memory T cells proliferate in situ and are involved in human graft-versus-host disease.
Journal: Science translational medicine
Published: March 12, 2020
Anti-Apoptotic Molecule BCL2 Is a Therapeutic Target in Steroid-Refractory Graft-Versus-Host Disease.
Journal: The Journal of investigative dermatology
Published: October 23, 2019
Extracorporeal photopheresis as second-line therapy for patients with acute graft-versus-host disease: does the number of cells treated matter?
Journal: Transfusion
Published: October 31, 2017
Umbilical Cord Blood Transplantation Is a Feasible Rescue Therapeutic Option for Patients Suffering from Graft Failure after Previous Hematopoietic Stem Cell Transplantation.
Journal: Oncology
Published: December 26, 2015
Last Updated: 09/26/2026